August J. Moretti - 15 May 2023 Form 4 Insider Report for 4D Molecular Therapeutics, Inc. (FDMT)

Reporting relationship: Chief Financial Officer
Issuer ticker: FDMT
Reported as of: 15 May 2023
Net transaction value: +$28,230
SEC form: 4
Accepted by SEC: 16 May 2023, 20:52:00 UTC
Prior SEC filing: 14 Feb 2023
Next SEC filing: 25 Nov 2024
Source filing: View source filing
Reporting owner signature: /s/ August J. Moretti

Key filing fact

August J. Moretti filed Form 4 for 4D Molecular Therapeutics, Inc. (FDMT) on 16 May 2023.

Key facts

This page summarizes August J. Moretti's Form 4 filing for 4D Molecular Therapeutics, Inc. (FDMT).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 16 May 2023, 20:52.

Change

Previous filing in this sequence was filed on 14 Feb 2023.
Current net transaction value: +$28,230.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

FDMT transaction

Common Stock

Options Exercise

Transaction value: $28,230
Shares: +3,000
Change %: +37%
Price: $9.41
Shares after: 11,045
Date: 15 May 2023
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

FDMT transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value: $0
Shares: -3,000
Change %: -1.4%
Price: $0.000000
Shares after: 217,060
Date: 15 May 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,000
Exercise price: $9.41
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Reflects 1,450 shares of the Issuer's common stock purchased under the Issuer's Employee Stock Purchase Plan in a transaction exempt from Rule 16b-3.

Footnote F2

The option is fully vested and exercisable

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .